Oxetane-Substituted Compounds for Bone Healing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current small molecule radiation mitigators face challenges in design and implementation due to relative insolubility, requiring unsuitable delivery systems and leading to compound degradation and precipitation issues, especially in aqueous solubility, which affects their efficacy in radiation-induced damage mitigation.
Innovation Solution
Development of oxetane-substituted compounds that enhance aqueous solubility and serve as radioprotectors and radiomitigators, including MMS350, which can be administered orally and effectively mitigate radiation-induced damage by increasing solubility and bioavailability, and accelerating bone healing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule radiation mitigators are used, then radiation-induced damage mitigation is achieved, but aqueous solubility is poor leading to compound precipitation and degradation
Solution Approach 1:
The patent introduces oxetane-substituted compounds as intermediary substances that enhance the aqueous solubility of radiation mitigators. These compounds act as mediators between the hydrophobic radiation mitigator molecules and the aqueous delivery system, enabling effective drug delivery without precipitation or degradation
Solution Approach 2:
The invention creates composite formulations combining radiation mitigator compounds with oxetane-substituted solubilizing agents. This composite approach allows the hydrophobic radiation mitigator to be delivered in aqueous systems while maintaining stability and preventing precipitation
2Ease of operation
If lipophilic compounds with higher molecular weight are used to enhance membrane permeability, then membrane permeability is improved, but aqueous solubility decreases leading to precipitation from DMSO stock solutions
Solution Approach 1:
Oxetane-substituted compounds serve as intermediary solubilizing agents that bridge the gap between lipophilic radiation mitigators and aqueous environments. These intermediaries enable the lipophilic compounds to maintain both membrane permeability and aqueous solubility through co-solvent or micellar delivery systems
3Quantity of substance
If DMSO is used as storage solvent for compound libraries, then compound storage is enabled, but compound degradation and precipitation occur over time
Solution Approach 1:
The patent applies parameter changes by modifying the storage medium from pure DMSO to formulations containing oxetane-substituted compounds. This parameter change in the storage system prevents degradation and precipitation of lipophilic compounds during long-term storage while maintaining compound availability
Data Source
AI summary
Disclosed herein are embodiments of a method of accelerating bone healing in a subject in need thereof, comprising administering to the subject a compound disclosed here. The method may further comprise selecting or identifying a subject that has bone damage, or is a risk of developing bone damage. The compound may be administered after bone damage has occurred, or it may be administered prophylactically. The compound may be administered to a subject that has not and/or will not be exposed to radiation. In other embodiments, the subject has been and/or will be exposed to radiation.